secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2026-02-02T23:59:59+00:00
Accession:  0001193125-26-032706
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics updates corporate presentation with estimated cash balance and pipeline milestones
--------------------------------------------------------------------------------

- Estimated cash, cash equivalents and short-term investments as of Dec 31, 2025 disclosed (amount not specified in filing).
- Phase 1/2 data expected across all three clinical programs during 2026.
- VMT-α-NET shows durable disease control and best-in-class safety profile in neuroendocrine tumors.
- VMT01 exhibits preliminary anti-tumor activity at lower doses in melanoma.
- PSV359 targeting FAP-α for solid tumors is ongoing in Phase 1/2a trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000119312526032706/0001193125-26-032706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000119312526032706/catx-20260202.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-032706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer